Interest of circulating tumor DNA as a biomarker for canine cancers: illustration in histiocytic sarcoma, oral malignant melanoma and multicentric lymphoma - Archive ouverte HAL Accéder directement au contenu
Pré-Publication, Document De Travail Année : 2020

Interest of circulating tumor DNA as a biomarker for canine cancers: illustration in histiocytic sarcoma, oral malignant melanoma and multicentric lymphoma

Anaïs Prouteau
  • Fonction : Auteur
Jérôme Alexandre Denis
  • Fonction : Auteur
Pauline de Fornel
  • Fonction : Auteur
Edouard Cadieu
  • Fonction : Auteur
Camille Kergal
  • Fonction : Auteur
Nadine Botherel
  • Fonction : Auteur
Ronan Ulvé
  • Fonction : Auteur
Mélanie Rault
  • Fonction : Auteur
Amira Bouzidi
  • Fonction : Auteur
Romain François
  • Fonction : Auteur
Laetitia Dorso
Alexandra Lespagnol
  • Fonction : Auteur
Patrick Devauchelle
  • Fonction : Auteur
Jérôme Abadie
Catherine André
  • Fonction : Auteur
Benoît Hédan
  • Fonction : Auteur

Résumé

Circulating tumor DNA (ctDNA) has become an attractive biomarker in human oncology and may be informative in cancer-affected dogs. By performing ddPCR or PARR methods, we detected tumor-specific point mutations, copy number alterations and chromosomal rearrangements in the plasma of cancer-affected dogs. It allowed the detection of ctDNA in 2/8 (25%) oral malignant melanoma cases, 12/13 (92.3%) lymphoma cases and 21/23 (91.3%) histiocytic sarcoma (HS) cases. The value of ctDNA to diagnose HS was explored in 133 dogs including 49 with HS. In this cohort, screening recurrent PTPN11 mutations in plasma had a specificity of 98.8%, and a sensitivity between 42.8-77% according to HS clinical presentation, being higher in internal forms, especially with pulmonary location. Regarding lymphoma, the follow-up of four dogs showed that the minimal residual disease detection by targeting lymphoma-specific antigen receptor rearrangement in the plasma was concordant with the clinical evaluation. Moreover, ctDNA analysis appeared interesting to assess treatment response and to predict relapse.
This study shows that ctDNA is detectable in the plasma of cancer-affected dogs and is a relevant biomarker for diagnosis and clinical follow-up. With a growing interest in integrating natural canine tumors to explore new therapies, this biomarker appears promising in comparative oncology research.

Dates et versions

hal-03007320 , version 1 (16-11-2020)

Identifiants

Citer

Anaïs Prouteau, Jérôme Alexandre Denis, Pauline de Fornel, Edouard Cadieu, Thomas Derrien, et al.. Interest of circulating tumor DNA as a biomarker for canine cancers: illustration in histiocytic sarcoma, oral malignant melanoma and multicentric lymphoma. 2020. ⟨hal-03007320⟩
26 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More